VistaGen Net Interest Income from 2010 to 2026
| VTGN Stock | USD 0.55 0.01 1.73% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 630 K | Current Value 647 K | Quarterly Volatility 539.9 K |
Check VistaGen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VistaGen Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 19.7 K, Selling General Administrative of 20.6 M or Other Operating Expenses of 68.2 M, as well as many indicators such as Price To Sales Ratio of 149, Dividend Yield of 4.21 or Invested Capital of 0.0. VistaGen financial statements analysis is a perfect complement when working with VistaGen Therapeutics Valuation or Volatility modules.
VistaGen | Net Interest Income | Build AI portfolio with VistaGen Stock |
Evaluating VistaGen Therapeutics's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into VistaGen Therapeutics's fundamental strength.
Latest VistaGen Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of VistaGen Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. VistaGen Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
VistaGen Net Interest Income Regression Statistics
| Arithmetic Mean | 1,098,672 | |
| Coefficient Of Variation | 189.31 | |
| Mean Deviation | 1,677,228 | |
| Median | (5,000) | |
| Standard Deviation | 2,079,951 | |
| Sample Variance | 4.3T | |
| Range | 5.5M | |
| R-Value | 0.74 | |
| Mean Square Error | 2.1T | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | 306,824 | |
| Total Sum of Squares | 69.2T |
VistaGen Net Interest Income History
About VistaGen Therapeutics Financial Statements
VistaGen Therapeutics investors utilize fundamental indicators, such as Net Interest Income, to predict how VistaGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 5.2 M | 5.5 M |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against VistaGen Stock
| 0.81 | DRTS | Alpha Tau Medical | PairCorr |
| 0.74 | GXEA | Galapagos NV | PairCorr |
| 0.71 | EQ | Equillium | PairCorr |
| 0.65 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.63 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of VistaGen Therapeutics Correlation against competitors. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could VistaGen diversify its offerings? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every VistaGen Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.90) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets | Return On Equity |
Investors evaluate VistaGen Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating VistaGen Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause VistaGen Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, VistaGen Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.